Each item carries a confidence level. Verbatim rule text is high confidence; a reading of how two provisions interact, or a source that could not be re-verified, is not.
- The regulation everyone cites was repealedHigh confidence
- 16 CCR § 1735.2, "Compounding Limitations and Requirements" — the rule cited across the industry as California’s office-use authority — was repealed effective October 1, 2025, along with all of the old Article 4.5 (§§ 1735–1735.8) and the old sterile series (§§ 1751 et seq.). Section 1735.2 today is titled "Personnel Training and Evaluation."Adopted by the Board March 26, 2025, Regulatory Action No. 2025-0507-02, filed with the Secretary of State June 19, 2025, effective October 1, 2025.
- The current architectureHigh confidence
- Sections 1735–1735.15 govern non-sterile compounding under USP 795; §§ 1736–1736.21 sterile under USP 797; §§ 1737–1737.17 hazardous under USP 800; §§ 1738 et seq. radiopharmaceutical under USP 825.
- Where the phrase "office use" actually appearsHigh confidence
- Twice in the entire Lawbook, and both times in a statute — Bus. & Prof. Code § 4052(a)(1) and § 4119.5(b). It appears zero times in the regulations. Every office-furnishing provision in the adopted regulations is veterinary.
- What the statute does not containHigh confidence
- No quantity cap, no day-supply limit, no administer-only restriction, no labelling legend, no sterile or non-sterile distinction, and no federal-law condition. Every one of those conditions lived in the regulation that was repealed.
- Veterinary caps — and they are veterinaryHigh confidence
- A 14-day supply for non-sterile preparations, 7 days for sterile, and 28 days for topical ophthalmic — each per individual animal patient, documented on a purchase order in advance.These numbers circulate as though they were general office-use limits. They are not. Reciting them without the word veterinary is one of the specific errors 05c flags.
- Quantity limits for human office useHigh confidence
- None exist, because the pathway does not exist in regulation. The old six-factor "reasonable quantity" test lived in the repealed § 1735.2(c) and went with it. Anyone citing a California human office-use quantity, day supply or per-practitioner limit is citing repealed law.
- Administer-onlyHigh confidence
- The explicit limitation survives only for veterinary offices (§§ 1735.1(d)(1) and 1736.1(d)(1), "solely in the veterinarian’s office"). For human use there is no authorised activity for it to limit.
- LabellingHigh confidence
- No "Not for Resale" legend exists in California law — the phrase appears zero times in the Lawbook. Current labelling requirements are § 1735.9 for non-sterile and § 1736.13 for sterile, both expressly "in addition to" USP 795 §7 and USP 797 §16.
- Recordkeeping and reportingHigh confidence
- Three years, with a full audit trail of revisions (§§ 1735.14 and 1736.20). Recall and adverse-event reporting to the Board runs within 12 hours (Bus. & Prof. Code §§ 4126.9, 4127.1(e)(3) and (f), 4127.2(e)(3) and (f)); immediate-use transitions within 72 hours (§ 1736.1(b)).
- The Board’s own website still publishes stale guidanceHigh confidence
- A live FAQ entry describes a reasonable quantity that may be compounded for prescriber office use as authorised by § 4052(a)(1), cites the repealed regulation as its reference, is marked "Revised January 2022", and sits in the section about outsourcing facilities. Expect a vendor or a client to produce it.High confidence that the text is live on the Board’s site. The guidance itself is stale and predates the rewrite. It is not a basis for copy or for a sourcing decision.
- Out-of-state pharmacies — two gates, one of which changed in July 2026High confidence
- Bus. & Prof. Code § 4112 was replaced effective July 1, 2026 with a broader trigger ("involved in the preparation, dispensing, shipping, mailing, or delivery"), a required California-licensed pharmacist-in-charge employed and working at the nonresident pharmacy, and Board inspection authority at the pharmacy’s expense. Separately, § 4127.2 bars a nonresident pharmacy from compounding sterile drug products for shipment into California without a sterile compounding pharmacy licence, and adds an annual on-site inspection by the California Board at the pharmacy’s expense. Most programmes fail that second gate.Section 4112(j) still limits registration to shipments "pursuant to a prescription", which cuts against office stock rather than for it: it suggests a pharmacy shipping office stock is operating outside the licensure scheme entirely, which is a worse posture, not a safer one. That reading is medium confidence.
- A drafting artifact worth knowing aboutHigh confidence
- Sections 4127.1(d)(2) and 4127.2(d)(2) still cross-reference the repealed § 1735.2 self-assessment form; the statutes were not conformed to the October 2025 rewrite. It is a citable inconsistency and it is not evidence that the old regulation survives.
- Interstate distributionHigh confidence
- Bus. & Prof. Code § 4126.10(a) — a California pharmacy may distribute compounded human drug preparations interstate only if it reports annually between January 1 and March 31 into the information-sharing network implementing the memorandum of understanding on certain distributions of compounded human drug products, certifies compliance at renewal, and reports adverse events and product quality issues to the Board within 12 hours. Any multi-state office-stock programme run out of a California pharmacy hits this directly.
- The conflict, stated honestlyMedium confidence
- Section 4052(a)(1) has not been repealed, and a lawyer could argue a statute controls over a regulation that merely declines to implement it. No California case, Attorney General opinion, declaratory ruling or disciplinary decision resolving the point was found. The Board did state the ceiling it believes it operates under: while it can strengthen federal requirements, it cannot promulgate a lesser standard in its regulations.Confidence in the underlying facts is high. Confidence that copy cannot rely on the statute alone is a risk judgment rather than a holding, which is why it is marked medium. This is the specific question to put to California regulatory counsel.
- Last changeHigh confidence
- The compounding regulations were fully rewritten effective October 1, 2025, removing human office use from the regulations. Section 4052 was amended by AB 1503 effective January 1, 2026 with subdivision (a)(1) retained. Section 4112 was replaced effective July 1, 2026. The Board’s FAQ was revised in January 2026. There is no pending rulemaking on compounding or office use — the pending items are fee schedules, remote processing and central fill.